Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1582 of 5804
-
New drug cocktail targets Hard-to-Treat colorectal cancer
Disease control CompletedThis study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the stu…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a diabetes drug boost radiation to fight returning prostate cancer?
Disease control OngoingThis phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin
Phase: PHASE1, PHASE2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a smart patch outsmart hidden heart risks after stroke?
Diagnosis OngoingIt is known that atrial fibrillation after stroke significantly increases the risk of stroke or systemic embolism. Accordingly, efforts have been made to detect hidden atrial fibrillation and apply treatment using anticoagulants instead of antiplatelet agents. The conventional me…
Phase: NA • Sponsor: Ewha Womans University Mokdong Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Could an implant replace daily eye drops for glaucoma?
Disease control OngoingThis is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pfizer drug takes on Hard-to-Treat cancers
Disease control Recruiting nowThis is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Newer scope technique may outperform standard procedure for Cancer-Related bile duct blockage
Disease control CompletedThe main objective is to compare the EUS-BD with the insertion of a LAMS vs. traditional ERCP to restore biliary patency. Although ERCP has been the primary treatment for many years, it is associated with a significant risk of procedural complications and possible stent blockage.…
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New balloon treatment aims to keep dialysis access open longer
Disease control OngoingLong-term safety will be summarized
Sponsor: Medtronic • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pacing technique may shield heart from failure in block patients
Disease control CompletedThis is a multicenter, randomized controlled study. The aim of this study is to compare the impact of LBBAP on left ventricular function as compared with traditional right ventricular pacing in patients with atrioventricular block.
Phase: NA • Sponsor: Fu Wai Hospital, Beijing, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could a 2-Day infusion save transplanted kidneys from early damage?
Disease control Recruiting nowThe objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is exp…
Phase: PHASE1, PHASE2 • Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New radioactive bullet targets Hard-to-Treat prostate cancer
Disease control OngoingThe purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the …
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug shows promise for Sjögren's syndrome in early trial
Disease control CompletedPrimary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activ…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Tailor-Made vaccine takes on advanced melanoma in early trial
Disease control OngoingThis research study is investigating a new type of personalized neoantigen vaccine, NeoVax, plus Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible treatment for cutaneous melanoma. The drugs involved in this study are: * Personalized Neoa…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for Hard-to-Treat myeloma: first human trial of forimtamig begins
Disease control CompletedThis is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies.…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo aims to tame deadly transplant complication
Disease control CompletedThis phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with acute leukemia, myelodysplastic syndrome or myelofibros…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Fish oil may protect babies of moms who smoke
Prevention CompletedSmoking is the most important modifiable risk factor for adverse pregnancy outcomes including preterm birth, neonatal death, and maternal complications. Rates of smoking cessation during pregnancy are low, particularly in underserved populations, and currently approved pharmacoth…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
Face-Down therapy could save COVID patients who refuse ventilators
Symptom relief CompletedThe purpose of this trial is to determine whether Prone Positioning (PP) improves outcomes for non-intubated hospitalized patients with hypoxemic respiratory failure due to COVID-19, who are not candidates for mechanical ventilation in the ICU. The investigators hypothesize that …
Phase: NA • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Super-Sized flu shot shows promise for seniors
Prevention CompletedPrimary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants. Safety: To describe the safety profile of all participan…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Can a Pre-Surgery diet cut complications in esophageal cancer?
Disease control OngoingThis randomized controlled trial will evaluate the effects of preoperative enteral immunonutrition in esophageal cancer patients undergoing neoadjuvant therapy. The purpose of this study is to determine whether preoperative immune-modulating diet before surgery can improve the ra…
Phase: PHASE3 • Sponsor: Hecheng Li M.D., Ph.D • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with resistant cancers? drug combo shows promise in early trial
Disease control CompletedThe study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatme…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC